Cempra, Inc. (CEMP)

Lifshitz & Miller announces investigation on behalf of CEMP investors concerning whether CEMP adequately disclosed the safety risks of CEMP's drug solithromycin for hepatotoxicity.

If you are a CEMP investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

CONTACT US

1190 Broadway

Hewlett, NY 11557

Office: (516) 493-9780

Fax: (516) 280-7376

 

​​​​© 2021 by Lifshitz Law Firm, P.C. All rights reserved. | Sitemap | Disclaimer | Proudly created with Wix.com

  • Grey Facebook Icon
  • Grey Twitter Icon
  • Grey LinkedIn Icon